Arrhythmias & electrophysiologyCohort study
Clinical and economic outcomes in diagnostic-naïve Medicare fee-for-service beneficiaries managed with alert-based ambulatory cardiac monitors: The CAMELOT-ALERT study
- retrospective cohort study
- 100% Medicare Fee-For-Service (FFS) claims from 2020 to 2022
- inverse probability of treatment weighting (IPTW)
Authors' conclusion
Diagnostic yield and retesting varied across ACM platforms, though residual confounding cannot be excluded. No differences were identified in outcomes, utilization, or costs. Randomized trials are warranted to determine true differences in platform performance.
Study context
- Population
- Arrhythmia diagnosis-naïve Medicare Fee-For-Service (FFS) beneficiaries aged 65 years or older, excluding those with prior arrhythmia diagnoses, antiarrhythmic medication use, or rhythm-management proceduresiRhythm mobile cardiac telemetry (MCT) 17,773 · Other MCT 368,830 · ambulatory event monitoring (AEM) 55,189
- Participants
- 441,792 eligible beneficiaries
- Exposure
- mobile cardiac telemetry or ambulatory event monitoring
- iRhythm MCTn = 17,773
- Other MCTn = 368,830
- AEMn = 55,189
Main finding
As reported in the abstract
Diagnostic yield · 90 days
Hazard ratio (95% CI)
iRhythm MCT and Other MCT
0.79(0.77–0.81)
iRhythm MCT and AEM
0.76(0.74–0.78)
Observational data: associations, not effects.
Further findings
Retesting · 180 days
| Comparison | iRhythm MCT | Other MCT | AEM | HR (95% CI) | |
|---|---|---|---|---|---|
| iRhythm MCT and Other MCT | 8.8% | 6.3% | 7.2% | 0.70 (0.66–0.74) | |
| iRhythm MCT and AEM | 0.81 (0.76–0.87) | ||||
| 0.512Hazard ratio (log scale) |
- Retesting: direction not stated in the abstract; retesting more frequent with iRhythm MCT
- Retesting: direction not stated in the abstract; retesting more frequent with iRhythm MCT
Pacemaker implantation
- Pacemaker implantation was more common with iRhythm MCT
Hospitalizations, emergency visits, heart failure
- no differences were identified in hospitalizations, emergency visits, or heart failure
Original publication
Clinical and economic outcomes in diagnostic-naïve Medicare fee-for-service beneficiaries managed with alert-based ambulatory cardiac monitors: The CAMELOT-ALERT study. Am Heart J. Published 31 August 2026. doi:10.1016/j.ahj.2026.107594
Summarised from the published abstract; every number is checked against it